Metastasizing Pleomorphic Salivary Adenoma | Oncology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Navigation Landing]
Original Article
July 2006

Metastasizing Pleomorphic Salivary Adenoma

Author Affiliations

Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Drs Nouraei, Clarke, and Sandhu) and Histopathology (Drs Sandison and Michaels), Charing Cross Hospital, London, England; Department of Paediatric Surgery, Great Ormond Street Hospital for Sick Children, London (Dr Ferguson); and Department of Head & Neck Surgery, Royal Marsden Hospital, London (Drs Clarke and Rhys-Evans). Dr Ferguson is now with the Department of Otolaryngology–Head and Neck Surgery, Barts and the London Hospital, London.

Arch Otolaryngol Head Neck Surg. 2006;132(7):788-793. doi:10.1001/archotol.132.7.788

Objective  To address questions about the etiology, behavior, optimal treatment, and prognosis of metastasizing pleomorphic adenoma (MPA), we undertook a review of the literature (1953-2005) and constructed a virtual series of all identified cases of MPA, metastatic lesions that are very occasionally identified in patients with a history of pleomorphic salivary adenoma and, on detailed pathological evaluation, found to exhibit all the histological hallmarks of the preceding benign lesions.

Data Sources  A review of the English-language literature between 1953 and 2005 using MEDLINE, secondary references identified from bibliographies of pertinent articles, and a further case from one of our institutions.

Data Synthesis  A virtual case series was constructed and quantitatively analyzed. Forty-two patients with an average age of 33 years were identified. There were 20 male and 22 female patients. There was an overwhelming history of incomplete surgery for pleomorphic salivary adenoma. Most patients had locoregional recurrences before metastasis, and the mean presentation-to-metastasis latency was 16 years. Bone was the most common site for metastases (45%), followed by the head and neck (43%) and lung (36%). There was significant morbidity and mortality from distant disease, with 5-year disease-specific and disease-free survival of 58% and 50%, respectively. Developing distant lesions within 10 years of the primary tumor and presence of metastases in multiple sites were independent predictors of survival on Cox regression analysis. Metastasectomy conferred significant survival advantage over nonoperative treatment (log-rank analysis, P<.02). Chemotherapy and radiotherapy were of limited value.

Conclusions  Meticulous surgery is crucial in preventing MPA. Metastatic disease carries significant morbidity and mortality and should be treated surgically when feasible.